Ei­sai is build­ing a be­spoke Cam­bridge re­search cen­ter with a $100M-plus plan to find new ways to tack­le Alzheimer's

With a steady drum­beat of bad news set to the tem­po of doom and gloom in the Alzheimer’s/de­men­tia re­search world play­ing in the back­ground, Ei­sai is cre­at­ing its own $100 mil­lion-plus plan to start fresh and blaze some new re­search trails that go be­yond tau and amy­loid be­ta.

The Japan­ese com­pa­ny is build­ing a 50,000-square-foot re­search home at the Alewife Re­search Cen­ter close to the heart of the hum­ming Cam­bridge, MA biotech hub. Draw­ing on cur­rent staffers from their An­dover site — which is be­ing shut down — and adding some new skill sets, com­pa­ny ex­ecs plan to as­sem­ble a team of more than 80 sci­en­tists at the Ei­sai Cen­ter for Ge­net­ics Guid­ed De­men­tia Dis­cov­ery.

They’re com­mit­ting more than $100 mil­lion to fund op­er­a­tions for the first three years, says the cen­ter’s new pres­i­dent, Nadeem Sar­war. Break­through re­search in­to hu­man ge­net­ics will form a foun­da­tion for this de­men­tia group, he adds, but will go fur­ther in build­ing up ex­per­tise in da­ta sci­ences, im­mun­ode­men­tia, dis­cov­ery tech­nolo­gies and pre­ci­sion chem­istry.

And they’ll be work­ing shoul­der-to-shoul­der. The new cen­ter is be­ing built ac­cord­ing to the de­mands of the cur­rent style: Open. (Even though staffers may not al­ways care for it.)

“Open of­fices, open lab and open style,” is the way Sar­war, who’s join­ing the move­ment cel­e­brat­ing the end of re­search si­los, de­scribes it.

Sar­war says they’re join­ing the mi­gra­tion in­to Cam­bridge in or­der to gain clos­er con­tacts with the full range of aca­d­e­m­ic and in­dus­try re­search groups. He adds that Ei­sai plans to set up col­lab­o­ra­tive deals with a set of new part­ners, rang­ing from the star­tups and spin­outs jump­ing in­to the are­na as well as the more es­tab­lished com­pa­nies and promi­nent aca­d­e­m­ic teams in the hub.

The big idea here is that if you can start with a bet­ter un­der­stand­ing of the dis­ease, and the var­i­ous trig­gers that may be in­volved, you can do a much bet­ter job at de­feat­ing it.

Ei­sai has a con­sid­er­able amount of ex­pe­ri­ence in clin­i­cal de­vel­op­ment in this field. The com­pa­ny is al­lied on a BACE drug with Bio­gen, which has had mixed re­sults. They have al­so been watch­ing care­ful­ly as the two lead piv­otal pro­grams for BACE — at Mer­ck and more re­cent­ly at Eli Lil­ly and As­traZeneca — went down in flames.

Ul­ti­mate­ly, says Sar­war, it’s prob­a­ble that the field will go the way of on­col­o­gy, look­ing for more com­plex com­bi­na­tion ap­proach­es as it strikes the dis­ease at dif­fer­ent stages of de­vel­op­ment. And that won’t come eas­i­ly or quick­ly, which is why they’re com­mit­ting to a decade worth of work.

“We have to keep try­ing, for pa­tients and fam­i­lies,” says Sar­war. “It’s one of the most dev­as­tat­ing ill­ness­es there is.”

Sci­en­tists will be mov­ing in­to the new cen­ter as it is be­ing pre­pared for a grand open­ing next spring.

Im­age: Nadeem Sar­war and Ei­sai’s Cam­bridge site. EI­SAI

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology

ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development

CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

Vertex has clinched a priority review for the all-important cystic fibrosis triple that will blaze the trail for treating a large group of patients unhelped by its current drugs.

FDA regulators have set a PDUFA date of March 19, 2020, just a year after the Boston biotech posted positive Phase III results showing that people with two F508del mutations experienced statistically significant improvements in lung function after a 4-week regimen of VX-445, tezacaftor and ivacaftor. After reviewing 24-week data among patients with one F508del mutation and one minimal function mutation — and thoroughly comparing the VX-445 triple with another combo featuring VX-659 on scores like safety, drug-drug interactions, and photosensitivity — Vertex ultimately went with VX-445.

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

Just a few weeks after bagging $80 million in a deal to collaborate with Gingko Bioworks on its special blend of engineered bacteria used for “living therapeutics,” little Synlogic in Boston $SYBX is tossing one of its two clinical programs after watching an early-stage study go down in defeat.

Their Phase Ib/IIa study for SYNB1020 to counter the accumulation of ammonia in the body, a condition called hyperammonemia or urea cycle disorder, floundered at the interim readout, forcing the biotech to kill it and reserve its cash for pipeline therapies with greater potential.

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

Last week, Elanco explicitly dodged answering questions about its rumored interest in Bayer’s animal health business in its post-earnings call. On Tuesday, the Eli Lilly spinoff disclosed it was purchasing the German drug maker’s veterinary unit in a cash-and-stock deal worth $7.6 billion. 

Elanco $ELAN has been busy on the deal-making front. In April, it laid out plans to swallow its partner, Kansas-based pet therapeutics company Aratana $PETX. A July report by Reuters suggested a potential Bayer deal was being explored, and Bloomberg last week said the deal was imminent, citing sources. 

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

Months ago, data on J&J’s $JNJ Invokana indicated the diabetes drug conferred cardiovascular (CV) benefit in patients who do and do not have preexisting CV disease. On Tuesday, AstraZeneca’s $AZN rival treatment, Farxiga, was shown to cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial.

The treatments, in addition to Jardiance from Eli Lilly $LLY, belong to a class of diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by curbing the absorption of glucose via the kidneys so that surplus glucose is excreted through urination.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.